Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

ABSTRACT:

Background

Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib dosing based on PK levels.

Methods

Patients were treated with sunitinib 37.5 mg once daily. At days 15 and 29 of treatment, plasma trough levels of sunitinib and N-desethyl sunitinib were measured. If the total trough level (TTL) was <50 ng ml(-1) and the patient did not show any grade ⩾3 toxicity, the daily sunitinib dose was increased by 12.5 mg. If the patient suffered from grade ⩾3 toxicity, the sunitinib dose was lowered by 12.5 mg.

Results

Twenty-nine out of 43 patients were evaluable for PK assessments. Grade ⩾3 adverse events were experienced in seven patients (24%) at the startin

SUBMITTER: Lankheet NA 

PROVIDER: S-EPMC4021528 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature